[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@DrRishabhOnco Avatar @DrRishabhOnco Dr Rishabh Jain

Dr Rishabh Jain posts on X about iii, matterhorn, iv, os the most. They currently have XXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence travel destinations currencies countries

Social topic influence iii, matterhorn #49, iv, os, combo, cohort, eps, signals, breast cancer, dcr

Top Social Posts #

Top posts by engagements in the last XX hours

"🎯 ARASAFE: Can dose-dense docetaxel make triplet therapy safer #ESMO25 ARASAFE Phase III mHSPC N=250 💊 Arms 🔹 Daro + ADT + Docetaxel XX mg/m Q3W (ARASENS standard) 🔹 Daro + ADT + Docetaxel XX mg/m Q2W (ARASAFE regimen) 📊 Results (Safety Population) ✅ Grade XX AEs: XXXX % vs XXXX % p = XXXXXX ✅ NAER (any-cause death/AE): XXXX % vs XXXX % p XXXXXXX ✅ PSA XXX ng/ml: XXXX % vs XXXX % 💉 Mean cumulative dose: 1073 mg (D50) vs XXX mg (D75) 📌 Conclusion: ARASAFE shows that Q2W XX mg/m docetaxel significantly cuts toxicity while maintaining PSA control - potentially a new safer standard for"
X Link @DrRishabhOnco 2025-10-17T08:08Z 3333 followers, 5458 engagements

"🎯 HARMONi-6 delivers new hope in 1L advanced squamous #NSCLC 🫁 📍 Phase III n=532 1L Stage IIIBIV sqNSCLC 💊 Arms: 🔹 Ivonescimab + chemo (20 mg/kg Q3W) 🔹 Tislelizumab + chemo (200 mg Q3W) Followed by monotherapy maintenance 📈 Results: PFS: XXXX mo vs XXX mo (HR XXXX 0.460.78 p0.0001) PD-L1 1%: XXX vs XXX mo (HR 0.55) PD-L1 1%: XXXX vs XXX mo (HR 0.66) ✅ Consistent benefit across subgroups ⚕ Safety: SAE XXXX % vs XXXX % Grade X hemorrhagic events XXX % vs XXX % 🧩 Takeaway: Ivonescimab-chemo shows superior PFS vs tislelizumab-chemo - emerging as a potential new 1L standard for advanced"
X Link @DrRishabhOnco 2025-10-19T00:12Z 3333 followers, 4557 engagements

"🔥 Liver Arsenal for Colorectal Cancer - who rules 2025 🎯 Resection still reigns but new contenders are rising fast. Heres how every liver-directed therapy stacks up 👇 🩺 X Resection & Ablation Gold standard if R0 & FLR adequate MWA RFA 🔥 COLLISION Trial 2025: MWA non-inferior to resection (5-yr OS XX% vs 58%) Combo resection + ablation hepatic failure same DFS/OS 💉 X Hepatic Artery Infusion (HAI) Targets arterial tumor flow high local FUDR dose 10-yr OS XX% vs XX% with adjuvant HAI Conversion to resection 3050 % 🔬 PUMP Trial ongoing (NCT05863195) ☢ X Trans-Arterial Radioembolization"
X Link @DrRishabhOnco 2025-10-11T20:10Z 3332 followers, 13.2K engagements

"#ESMO25 X Days to go Here are my top X GI trials 🎤 MATTERHORN (LBA81) ✨ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎸 CheckMate 8HW (LBA29) ✨ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🥁Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎸 DYNAMIC-III (LBA9) ✨ ctDNA-guided adjuvant chemo in stage III CRC. 👉 Whats yours PS- @elonmusk grok is amazing #OncoTwitter #GastroOncology #GIcancer #LiverCancer #ColorectalCancer #ESMO25 @OncoAlert @myesmo @esmo_open @JCO_ASCO @ASCO @VivekSubbiah"
X Link @DrRishabhOnco 2025-10-16T17:49Z 3333 followers, 1098 engagements

"🎯 MATTERHORN delivers: Durvalumab + FLOT lifts survival in resectable gastric / GEJ adenocarcinoma 🔥 #ESMO25 Phase X n XXX D 1500 mg Q4W + FLOT vs Placebo + FLOT ✅ Improved EFS & OS (HR XXXX XX % CI 0.63-0.96 p = 0.021) 💪 Benefit seen irrespective of PD-L1 status (1 % & X %) 🧩 Higher ypN-neg rates (58 % vs XX %) + strong path response benefit 📈 EFS gain across pCR MPR & any path response 💡 Takeaway: Durvalumab + FLOT not only boosts EFS but achieves a clinically meaningful OS improvement - a new peri-operative standard for G/GEJ adenocarcinoma at #ESMO25 🚀 #OncoTwitter #GastricCancer"
X Link @DrRishabhOnco 2025-10-17T05:18Z 3333 followers, 6973 engagements

"🎯 ALEX delivers the long game Final 7-year update at #ESMO25 🧬 📍 Phase III ALK+ advanced NSCLC 💊 Alectinib (600 mg BID) vs Crizotinib (250 mg BID) 🧩 Results: Median OS XXXX mo vs XXXX mo (HR XXXX 0.561.08) 7-yr OS rate XXXX % vs XXXX % PFS (earlier readout): XXXX mo vs XXXX mo CNS benefit consistent across subgroups ⚕ Safety: All-grade AEs XX % G3-5 AEs XX % (balanced) Most common: bilirubin (alectinib) ALT (crizotinib) ✅ Takeaway: Durable survival cleaner toxicity and lasting CNS control - alectinib remains the benchmark 1L ALK TKI. #OncoTwitter #MedTwitter #LungCancer #ESMO25"
X Link @DrRishabhOnco 2025-10-17T18:19Z 3333 followers, 2618 engagements

"🔥 Chemo-IO climbs the MATTERHORN Durvalumab + FLOT ⛰ lifts peri-operative gastric/GEJ cancer outcomes at #ESMO25 ✅ OS HR XXXX (p = 0.021) ✅ Higher pCR & EFS gains across PD-L1 + node-positive & diffuse subgroups 💪 Median OS NR in both arms but curves clearly part ways 📊 Durvalumab + FLOT sets a new standard for fit resectable disease. #OncoTwitter #GastricCancer #Immunotherapy #ESMO25 @OncoAlert @myesmo @esmo_open"
X Link @DrRishabhOnco 2025-10-17T19:21Z 3333 followers, 3122 engagements

"🔥 From ineligible ➜ unbeatable: EV + Pembro raises the bar in MIBC 📍 KEYNOTE-905 / EV-303 (Phase III) Peri-op EV + Pembrolizumab vs Observation in cis-ineligible or declining MIBC 🎯 Primary EFS (BICR): HR XXXX (95% CI 0.280.57) P XXXXXX 💪 Secondary OS: HR XXXX (95% CI 0.330.74) P = XXXXXX 24-mo EFS: XXXX % vs XXXX % 24-mo OS: XXXX % vs XXXX % 👥 n = XXX Median age XX y XX % cis-ineligible ✅ EV + Pembro sets a new peri-operative benchmark for patients without cisplatin options. #ESMO25 #OncoTwitter #BladderCancer @OncoAlert @myesmo @esmo_open @JCO_ASCO"
X Link @DrRishabhOnco 2025-10-18T16:37Z 3333 followers, 1750 engagements

"🎯 Dato-DXd doubles ORR & improves survival in 1L TNBC 💪🩸 #TROPIONBreast02 Phase III 1L inoperable/metastatic TNBC 💊 Arms: 🔹 Dato-DXd X mg/kg Q3W (n=323) 🔹 Investigators choice chemo (ICC n=321) 📈 Results (BICR): ORR: XXXX% vs XXXX% ( +33%) CR: X% vs XXX% Median PFS: XXXX mo vs XXX mo (HR 0.57) Median OS: XXXX mo vs XXXX mo (HR 0.79) ✅ Takeaway: Dato-DXd significantly improved PFS (+5.3 mo) and OS (+5.0 mo) vs chemo #ESMO25 #OncoTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @AnnOncology"
X Link @DrRishabhOnco 2025-10-19T08:33Z 3333 followers, 1094 engagements

"🧬 Aging & Immunity: Time to Update Normal Lymphocyte Ranges A massive UK dataset (45780 FBCs) reveals ALC falls X% per decade yet labs still use a fixed adult cutoff (1.04.0 10/L) 🧪 ➡ Mislabels up to X in X elderly as lymphopenic 👩⚕ Proposed fix: age-specific reference intervals 1829 yrs Lower 2.5th = XXXX 10/L XX yrs Lower 2.5th = XXXX 10/L 🧓🏽 Adjusting by age slashes false-positive lymphopenia rates & patient anxiety. 🧠 Takeaway: Like pediatric labs adult hematology must go age-smart. 📊 Precision begins with proper reference intervals. 📖 Elmahdi et al. Am J Hematol 2025. 🔗 #ESMO25"
X Link @DrRishabhOnco 2025-10-19T18:29Z 3333 followers, 2348 engagements

"💥 SCLC finally meets its match B7-H3 ADC delivers nearly XX % responses where chemo had none 💥 🫁 Phase II IDeate-Lung01 (J Clin Oncol 2025; Rudin et al. DOI 10.1200/JCO-25-02142*) 🌍 Global n = XXX B7-H3 ADC XX mg/kg Q3W 💊 Treatment Ifinatamab Deruxtecan (I-DXd) XX mg/kg IV every X weeks after X prior line 📊 Key Results (12 mg/kg cohort n = 137) ✨ ORR: XX % (95 % CI 39.656.9) 🧩 DCR: XX % Median DOR: XXX mo 📆 PFS: XXX mo (95 % CI 4.25.5) OS: XXXX mo (95 % CI 9.113.3) 🔹 2L subset: ORR XX % OS XX mo 🧠 Brain mets: Systemic & CNS ORR XX % ⚠ Safety 🧾 TRAEs any-grade XXXX % G3 XXXX % 🤢"
X Link @DrRishabhOnco 2025-10-15T13:06Z 3312 followers, 4963 engagements

"#ESMO25 🦙 LBA37 ALPACA Trial Avelumab in Advanced Penile Cancer 🧬 When platinum fails can PD-L1 blockade help this rare disease 📍 Phase II Single-arm n = XX Advanced / Metastatic PSCC Eligible: unfit for or progressed after platinum-based chemo 💉 Treatment: Avelumab XX mg/kg IV q2 weeks 🎯 Primary EP: ORR (iRECIST) 📈 Secondary EPs: PFS OS Safety 📊 Results at ESMO25 👨⚕ Median age XX (41-72); ECOG XX in all 🧪 Prior chemo: XX % 🌀 Median X cycles (172) ✅ Partial response: X pts (17 %) ➖ Stable disease: X pt (4 %) ❌ Progressive disease: XX pts (78 %) ➡ Clinical Benefit Rate: XX % Median"
X Link @DrRishabhOnco 2025-10-17T06:24Z 3307 followers, 2834 engagements

"🔥 Rare cancer real response 🧬 Avelumab shows glimmers of hope in advanced penile cancer - ALPACA trial @ #ESMO25 📍 Multicenter single-arm Phase II (n=23) 💉 Avelumab XX mg/kg IV q2w till progression Key Results: 🔹 ORR XX % (4 PRs) DCR XX % mDOR XXXX mo mPFS XXX mo mOS XXX mo ⚕ Median X cycles (range 172) ✅ No new safety signals Grade 3+ AEs X % 💡 Even in ultra-rare chemo-refractory penile cancer checkpoint inhibition delivers a spark. #ESMO25 #OncoTwitter #Immunotherapy #PenileCancer @OncoAlert @esmo_open @myesmo"
X Link @DrRishabhOnco 2025-10-17T19:16Z 3312 followers, 1456 engagements

"🌊 The next ADC wave hits HR+/HER2- disease and its called Sac-TMT 📍 OptiTROP-Breast02 Phase III n = XXX 💊 Sac-TMT (5 mg/kg Q2W) vs Investigators-choice chemo (eribulin / cape / gem / vinorelbine) 📊 Efficacy snapshot: 🔹 mPFS XXX mo vs XXX mo (HR XXXX 0.260.48 p 0.0001) 🔹 OS trend HR XXXX (0.180.61) 🔹 ORR XXXX % vs XXXX % ( XXXX %) 🔹 DCR XX % vs XX % ( XXXX %) 💡 DoR XXX vs XXX mo (HR 0.29) ✅ Sac-TMT sets a new benchmark for heavily pre-treated HR+/HER2- breast cancer. #ESMO25 #OncoTwitter #BreastCancer #MedTwitter @OncoAlert @myesmo @esmo_open"
X Link @DrRishabhOnco 2025-10-18T17:03Z 3311 followers, 1699 engagements

"🧪 FDG-PET lights the path to prognosis in soft tissue sarcoma ✨ 🎯 Prospective trial: PLD + Ifos 🔹 Metabolic response = XX % drop in SUVmax 🔹 PET time-points: after cycle X (1) & after cycle X / pre-op (2) 📊 Key Results ✅ 10-yr PFS: XX % vs XX % (1 responders vs non-responders; p = .008) ✅ 10-yr OS: XX % vs XX % (2 responders vs non-responders; p = 0.00026) 🔁 XX / XX X non-responders converted to responders by X 🧫 PET response correlated with greater tumor necrosis 💡 Why It Matters FDG-PET can risk-adapt neoadjuvant therapy Dont drop therapy after X cycle if X looks cold late metabolic"
X Link @DrRishabhOnco 2025-10-11T13:48Z 3324 followers, 5020 engagements

"🎶 The Fab X of #ESMO25 GI Trials 🎶 (The Beatles of GI oncology) 👑 Paul MATTERHORN (LBA81) ✨ The melodic leader 🎤 ➡ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎶 Setting the rhythm for peri-operative immunotherapy. 🎸 John CheckMate 8HW (LBA29) ✨ The bold visionary 🎸 ➡ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🎶 Still redefining the long-term harmony of immunotherapy. 🥁 Ringo Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ The steady backbone 🥁 ➡ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎶 Keeping the beat for triplet IO therapy in hepatocellular carcinoma. 🎹 George"
X Link @DrRishabhOnco 2025-10-12T14:35Z 3331 followers, 7087 engagements

"🚦 Hazard Ratio (HR) - your survival trials speedometer 🏁 Ever seen HR = XXX and wondered what it really means Lets decode 👇 🧭 HR compares how fast bad events happen ➡ Death relapse or progression - whatever the trial tracks. 📊 Interpretation: ⚖ HR = X No difference 💪 HR X Treatment slows events (good ✅) ⚠ HR X Events faster on treatment (bad ❌) 🧩 Example: HR = XXX New drug reduces risk by XX% (1 XXX = 0.3) Patients live longer or progress slower 🎯 Confidence Interval (CI) = how sure we are If it doesnt cross X the result is statistically solid 💥 💡 Easy memory: Kaplan-Meier curves ="
X Link @DrRishabhOnco 2025-10-13T15:26Z 3332 followers, 53.3K engagements

"🎯 ALEX delivers the long game - 1L Alectinib hits 6.5-year median OS in ALK NSCLC 🫁 #ESMO25 💊 Arms 🔹 Alectinib XXX mg BID 🔹 Crizotinib XXX mg BID 📊 Final Results OS : XXXX mo vs XXXX mo (HR XXXX 0.561.08) 🎯 DoR : XXXX mo vs XXXX mo (HR XXXX 0.300.56) 📈 PFS (prior) : XXXX mo vs XXXX mo 🧠 CNS benefit : consistent irrespective of baseline mets ⚕ Safety 💥 Grade X AEs : XX % vs XX % Median Tx duration : XXXX vs XXXX mo 🩺 Profile consistent with previous reports ✅ Takeaway 🕰 Durable OS XXX yrs + deep CNS control = Alectinib remains the global 1L standard for ALK NSCLC. #OncoTwitter"
X Link @DrRishabhOnco 2025-10-17T09:38Z 3333 followers, 4400 engagements

"💫 HER2-low HER2-zero No problem. Sacituzumab Tirumotecan (Sac-TMT) breaks barriers in HR+ breast cancer doubling PFS with consistent benefit across subgroups 🔥 📊 LBA23 #ESMO25 OptiTROP-Breast02 Phase III n = XXX HR+/HER2- mBC (53 % HER2-zero) 🧪 Prior CDK4/6 X chemo line 💊 Sac-TMT X mg/kg Q2W vs Investigators Choice (eribulin / vinorelbine / capecitabine / gemcitabine) 📈 Results 🕒 Median PFS XXX vs XXX mo (HR XXXX XX % CI 0.260.48; p 0.0001) 📆 6-mo PFS XX % vs XX % 🎯 ORR XX % vs XX % 🔹 HER2-zero (HR 0.39) HER2-low (HR 0.31) 💫 OS trend HR XXXX (immature) ⚕ Safety G3 TRAEs XX %"
X Link @DrRishabhOnco 2025-10-18T04:37Z 3332 followers, 4783 engagements

"🥊 ADC vs ADC in 1L mTNBC Two TROP2 titans go head-to-head for PD-L1-neg mTNBC 👇 🩵 Sacituzumab Govitecan (ASCENT-03) ⚡ PFS OS pending (crossover allowed) 🤢 More neutropenia + GI tox X infusions/cycle 💚 Datopotamab Deruxtecan (TROPION-Breast02) 🌟 PFS + OS endpoints (no crossover) 👁 Ocular + mucosal tox X infusion/cycle shorter time 🧠 Hot debates: crossover CNS mets HR-low BRCA resistance 🎤 Discussant: Ana Garrido-Castro #ESMO25 #OncoTwitter #BreastCancer @OncoAlert @myesmo @esmo_open @asco"
X Link @DrRishabhOnco 2025-10-19T09:23Z 3333 followers, 2729 engagements

"🚭 Lung Cancer in Never-Smokers Yes and its rising fast 🫁📈 🧩 Key facts from Murphy et al. JAMA 2025: 15-20% of all lung cancers occur in never-smokers Median age at dx XX y (younger than smokers XX y) 🌏 Rising incidence esp in Asian women (up to XX% cases in Taiwan) 🔬 60-80% adenocarcinoma ⚠ Major risks: passive smoke radon PM2.5 pollution asbestos family hx 🧠 Genomics: 🧬EGFR (43%) & ALK (12%) vs XX% & X% in smokers 🧬Low TMB (03 mut/Mb vs 030) = poorer IO response 💊 Therapy: Adjuvant osimertinib 5-yr OS XX% vs XX% (placebo) Alectinib DFS XX% vs XX% Immunotherapy alone 🪫 limited"
X Link @DrRishabhOnco 2025-10-21T15:32Z 3333 followers, 5069 engagements